Biocon Limited — Updates, 11-12-2024: Press Release

Biocon Biologics has been recognized as an Asia IP Elite for 2024 by IAM, marking the eighth consecutive year on this prestigious list. This recognition highlights the subsidiary's leadership in intellectual property excellence, reflecting its commitment to innovation and significantly enhancing its reputation as a global biosimilars company. Biocon Biologics is one of only two Indian pharmaceutical companies included in the elite group of 93 organizations acknowledged for exceptional IP value creation in the region.

CEO Shreehas Tambe emphasized the importance of their robust IP strategy, which is central to their business and vital for providing affordable biosimilar therapies worldwide. Biocon Biologics leverages its integrated capabilities to ensure early market entry of biosimilars, potentially enhancing its market share and growth trajectory. This accolade not only strengthens its competitive advantage but also signals a positive outlook for stakeholders as it continues to capitalize on its innovative approaches in the biosimilars market.